Federal contract award
75A50123C00048
CONDUCT A PHASE 2B EFFICACY STUDY AS PRESCRIBED IN AOI15 WITH COVILIV A PROPRIETARY LIVE ATTENUATED VIRUS COVID-19 VACCINE.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN42 — HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $10.0M |
| Current contract value | $57.6M |
| Potential contract value / ceiling | $389.4M |
| Start date | Sep 30, 2023 |
| Current end date | Jun 30, 2025 |
| Potential end date | Jul 31, 2026 |
| Latest award activity | Mar 11, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 2 of 2 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 11, 2026 | P00008 | $0 | EOI::PRESIDENTIAL COST SAVINGS INITIATIVE (FEBRUARY 26, 2025)::EOI MODIFICATION TO TRANSMIT FPDS DATA |
| Dec 6, 2024 | P00007 | $0 | CONDUCT A PHASE 2B EFFICACY STUDY AS PRESCRIBED IN AOI15 WITH COVILIV A PROPRIETARY LIVE ATTENUATED VIRUS COVID-19 VACCINE. |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.